Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Aging (Albany NY) ; 13(9): 12359-12377, 2021 05 05.
Artigo em Inglês | MEDLINE | ID: mdl-33952723

RESUMO

Age-related macular degeneration (AMD) is a worldwide leading cause of blindness affecting individuals over 50 years old. The most aggressive form, wet AMD, is characterized by choroidal neovascularization (CNV) and inflammation involving microglia recruitment. By using a laser-induced CNV mouse model, we provide evidence for a key role played by miR-142-3p during CNV formation. MiR-142-3p was overexpressed in murine CNV lesions and its pharmacological inhibition decreased vascular and microglia densities by 46% and 30%, respectively. Consistently, miR-142-3p overexpression with mimics resulted in an increase of 136% and 126% of blood vessels and microglia recruitment. Interestingly, miR-142-3p expression was linked to the activation state of mouse microglia cells as determined by morphological analysis (cell solidity) through a computational method. In vitro, miR-142-3p overexpression in human microglia cells (HMC3) modulated microglia activation, as shown by CD68 levels. Interestingly, miR142-3p modulation also regulated the production of VEGF-A, the main pro-angiogenic factor. Together, these data strongly support the unprecedented importance of miR-142-3p-dependent vascular-inflammation axis during CNV progression, through microglia activation.


Assuntos
Neovascularização de Coroide/tratamento farmacológico , Neovascularização de Coroide/genética , Lasers , MicroRNAs/farmacologia , Animais , Neovascularização de Coroide/patologia , Modelos Animais de Doenças , Injeções Intravítreas/métodos , Ativação de Macrófagos/genética , Degeneração Macular/tratamento farmacológico , Degeneração Macular/metabolismo , Camundongos , Microglia/efeitos dos fármacos , Microglia/metabolismo
2.
Sci Rep ; 8(1): 11922, 2018 08 09.
Artigo em Inglês | MEDLINE | ID: mdl-30093686

RESUMO

Diabetic retinopathy (DR) is one of the major complications of diabetes, which eventually leads to blindness. Up to date, no animal model has yet shown all the co-morbidities often observed in DR patients. Here, we investigated whether obese 42 weeks old ZSF1 rat, which spontaneously develops diabetes, hypertension and obesity, would be a suitable model to study DR. Although arteriolar tortuosity increased in retinas from obese as compared to lean (hypertensive only) ZSF1 rats, vascular density pericyte coverage, microglia number, vascular morphology and retinal thickness were not affected by diabetes. These results show that, despite high glucose levels, obese ZSF1 rats did not develop DR. Such observations prompted us to investigate whether the expression of genes, possibly able to contain DR development, was affected. Accordingly, mRNA sequencing analysis showed that genes (i.e. Npy and crystallins), known to have a protective role, were upregulated in retinas from obese ZSF1 rats. Lack of retina damage, despite obesity, hypertension and diabetes, makes the 42 weeks of age ZSF1 rats a suitable animal model to identify genes with a protective function in DR. Further characterisation of the identified genes and downstream pathways could provide more therapeutic targets for the treat DR.


Assuntos
Nefropatias Diabéticas/genética , Retinopatia Diabética/genética , Modelos Animais de Doenças , Perfilação da Expressão Gênica/métodos , Hipertensão/genética , Obesidade/genética , Animais , Glicemia/metabolismo , Cristalinas/genética , Cristalinas/metabolismo , Diabetes Mellitus Experimental/sangue , Diabetes Mellitus Experimental/genética , Diabetes Mellitus Experimental/metabolismo , Nefropatias Diabéticas/metabolismo , Retinopatia Diabética/metabolismo , Hipertensão/metabolismo , Masculino , Síndrome Metabólica/genética , Síndrome Metabólica/metabolismo , Neuropeptídeo Y/genética , Neuropeptídeo Y/metabolismo , Obesidade/metabolismo , Ratos , Retina/metabolismo , Retina/patologia
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa